secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-08-13T20:15:21+00:00
Accession:  0001104659-26-095931
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q2 2026 revenue up 14% to $18.7M; net loss $2.5M vs prior-year income
--------------------------------------------------------------------------------

- Q2 2026 net revenue $18.7M (up 14% YoY from $16.4M); net loss attributable to common stockholders $(2.5)M ($0.08/share) vs net income $13.4M ($0.50/share) in Q2 2025.
- Cash and equivalents $196.6M at June 30, 2026, up from $79.4M at Dec 31, 2025, boosted by $205M PRV sale from ZYCUBO.
- Crystalys closed $130M Series B financing for dotinurad; Urica holds equity and 3% royalty on future net sales.
- Journey Medical expanded Emrosi payer access to over 150M commercial lives (~85% of US commercial lives); Q2 net product revenue $17.8M vs $15.0M YoY.
- AstraZeneca reported anselamimab subgroup analysis: 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis; regulatory submission planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/0001104659-26-095931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926095931/fbio-20260813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer